+65,302.9%
NFLX vs GSK
+227.4%
+65,075.5%
-82.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.3% | -1.9% | -3.4% | -4.6% |
| 7D | -4.2% | -1.8% | -2.4% | -3.6% |
| 30D | +5.5% | -2.2% | +7.6% | +6.3% |
| 3M | -4.1% | -1.8% | -2.2% | -3.5% |
| 6M | -20.7% | -10.6% | -10.1% | -17.8% |
| YTD | -16.5% | +4.4% | -21.0% | -18.5% |
| 1Y | -37.8% | +30.4% | -68.2% | -44.4% |
| 3Y | +77.9% | +60.1% | +17.8% | +41.8% |
| 5Y | +32.5% | +46.8% | -14.3% | +7.7% |
| 10Y | +703.6% | +79.2% | +624.3% | +486.3% |
| All | +65,302.9% | +227.4% | +65,075.5% | +32,347.2% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling